Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Dillon K McCarty"'
Publikováno v:
Case Reports in Hematology, Vol 2020 (2020)
Ibrutinib is approved for the first-line treatment of chronic lymphocytic leukemia (CLL). A well-known side effect of ibrutinib therapy is increased bleeding risk, which ranges from mild mucocutaneous bleeding to rarely life-threatening hemorrhage. T
Externí odkaz:
https://doaj.org/article/501aed1704af431d9d7f4352b1599d1e
Publikováno v:
Case Reports in Hematology, Vol 2020 (2020)
Case Reports in Hematology
Case Reports in Hematology
Ibrutinib is approved for the first-line treatment of chronic lymphocytic leukemia (CLL). A well-known side effect of ibrutinib therapy is increased bleeding risk, which ranges from mild mucocutaneous bleeding to rarely life-threatening hemorrhage. T
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::70623356bafdce0c4b70ae50c93a0acc
https://doaj.org/article/501aed1704af431d9d7f4352b1599d1e
https://doaj.org/article/501aed1704af431d9d7f4352b1599d1e